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Abstract
Background: Elucidating the role of the underlying risk factors for severe outcomes of the 2009 A/H1N1 influenza pandemic
could be crucial to define priority risk groups in resource-limited settings in future pandemics.
Methods: We use individual-level clinical data on a large series of ARI (acute respiratory infection) hospitalizations from
a prospective surveillance system of the Mexican Social Security medical system to analyze clinical features at presentation,
admission delays, selected comorbidities and receipt of seasonal vaccine on the risk of A/H1N1-related death. We
considered ARI hospitalizations and inpatient-deaths, and recorded demographic, geographic, and medical information on
individual patients during August-December, 2009.
Results: Seasonal influenza vaccination was associated with a reduced risk of death among A/H1N1 inpatients (OR = 0.43
(95% CI: 0.25, 0.74)) after adjustment for age, gender, geography, antiviral treatment, admission delays, comorbidities and
medical conditions. However, this result should be interpreted with caution as it could have been affected by factors not
directly measured in our study. Moreover, the effect of antiviral treatment against A/H1N1 inpatient death did not reach
statistical significance (OR = 0.56 (95% CI: 0.29, 1.10)) probably because only 8.9% of A/H1N1 inpatients received antiviral
treatment. Moreover, diabetes (OR = 1.6) and immune suppression (OR = 2.3) were statistically significant risk factors for
death whereas asthmatic persons (OR = 0.3) or pregnant women (OR = 0.4) experienced a reduced fatality rate among A/
H1N1 inpatients. We also observed an increased risk of death among A/H1N1 inpatients with admission delays .2 days
after symptom onset (OR = 2.7). Similar associations were also observed for A/H1N1-negative inpatients.
Conclusions: Geographical variation in identified medical risk factors including prevalence of diabetes and immune
suppression may in part explain between-country differences in pandemic mortality burden. Furthermore, access to care
including hospitalization without delay and antiviral treatment and are also important factors, as well as vaccination
coverage with the 2008–09 trivalent inactivated influenza vaccine.
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Introduction
A number of researchers have explored the clinical and
epidemiological characteristics of novel A/H1N1 influenza in
different populations around the globe (e.g.,
[1,2,3,4,5,6,7,8,9,10,11,12]), but analyses of large individual-level
clinical data spanning multiple geographic regions and disease
severity outcomes of A/H1N1 infections are scarce. These studies
could be crucial to quantify the role of underlying population
health, case management, hospital admission delays and potential
changes in the influenza virus characteristics on the mortality
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burden of the 2009 A/H1N1 influenza pandemic across countries
[13].
The 2009 A/H1N1 influenza pandemic virus spread heteroge-
neously throughout Mexico [14,15,16,17], in a series of three
pandemic waves in the spring, summer, and fall of 2009, which
were associated with high mortality impact relative to other
countries [13,18,19]. Although a preliminary analysis of the
epidemiological characteristics and risk factors for A/H1N1
influenza infections has been carried out for the spring-summer
pandemic period in Mexico [14,15,16,20], a comprehensive
analysis of the fall pandemic wave during which most of the
deaths occurred, has not been carried out. Moreover, preliminary
studies conducted in Mexico during the early pandemic phase
suggested significant partial protection to novel 2009 A/H1N1
influenza conferred by the 2008–09 trivalent inactivated influenza
vaccine (TIV) [20,21]. Whether vaccination with the 2008–2009
seasonal influenza vaccine was significantly associated with
a reduced risk of death in the fall has yet to be evaluated. In
this article we fill this gap and carry out an analysis of clinical
features at presentation, hospital admission delays, medical
conditions, and receipt of seasonal vaccine on the risk of A/
H1N1-related death among hospitalized patients. We use in-
dividual-level data from a prospective surveillance system im-
plemented by the largest Mexican Social Security medical system
spanning August-December, 2009.
Materials and Methods
Epidemiological Data
Individual level hospitalization data were available from a pro-
spective epidemiological surveillance system implemented during
the 2009 influenza pandemic by the Mexican Institute for Social
Security (IMSS) [18,20]. IMSS is a tripartite Mexican health
system covering approximately 40% of the Mexican population
comprising workers in the private sector and their families, relying
on a network of 1,099 primary health-care units and 259 hospitals
nationwide. The age and gender distributions of persons affiliated
to the IMSS medical system are representative of the general
Mexican population [18]. Respiratory swabs were obtained for
approximately a third of cases with constant sampling intensity
across states, time, and age groups [18]. Swabs were tested for
pandemic A/H1N1 influenza virus by rRT-PCR by La Raza, an
IMSS laboratory certified by the Instituto de Diagno´stico y
Referencia Epidemiolo´gica (InDRE).
We analyzed information from all hospitalizations and in-
patient-deaths among patients admitted with acute respiratory
infection (ARI) during the fall pandemic wave from August
through December, 2009; the time period associated with
widespread A/H1N1 activity particularly affecting northern and
central Mexican states and coincided with the return of students
from summer vacations [18]. ARI was defined as any person with
respiratory difficulty presenting fever 38uC and cough, combined
with one or more of the following clinical symptoms: confinement
to bed, thoracic pain, polypnea, or acute respiratory distress
syndrome. Children ,5 years with pneumonia or severe pneu-
monia that required hospitalization were also considered as ARI
cases.
For each ARI inpatient, we recorded demographic information
(age in yrs, and gender), pandemic A/H1N1 status (positive,
negative; for those tested by RT-PRC), reporting state (including
31 states plus the Federal District), clinical signs and symptoms at
presentation (fever, cough, headache, sore throat, malaise,
myalgia, rhinorrhoea, arthralgias, myalgia, prostration, thoracic
pain, abdominal pain, conjunctivitis, nasal congestion, cyanosis,
diarrhea, dyspnea, and coryza), underlying risk factors (chronic
obstructive pulmonary disease (COPD), diabetes, smoking, obesi-
ty, pregnancy, lactating mother, immune status, asthma, and
HIV/AIDS status), dates of onset of symptoms (self-reported) and
hospitalization and discharge, whether the patient was treated with
neuraminidase inhibitors, and the 2008–09 trivalent inactivated
influenza vaccine (TIV) status. In Mexico, antiviral treatment with
neuraminidase inhibitors (Oseltamivir and Zanamivir) was con-
sidered for patients upon initial clinical evaluation and individual
risk of developing complications [22]. Specifically, antiviral
treatment was recommended for all cases presenting severe
symptoms, irrespective of age or underlying conditions. For cases
presenting mild symptoms, antiviral treatment was recommended
for high-risk patients only, which included infants ,5 y, seniors
.65 y, persons with lung disease (including asthma), cardiovas-
cular disease (except for systemic arterial hypertension), renal
disease, hematologic disease, neurologic disease, neuromuscular or
metabolic disorders (including diabetes), and immune deficiency
disease.
We defined the admission delay as the time elapsed from
symptoms onset to hospitalization admission, and hospital length of
stay was defined as the number of days from hospital admission to
discharge or death. Given that recommendations for neuramin-
idase inhibitors stipulate that treatment should be provided within
48 h of disease onset, we stratified admission delay into two groups
,= 2 and .2 days.
Statistical Analysis
We used univariate and multivariate logistic regression models
to assess the risk of death among A/H1N1-positive ARI inpatients.
In particular we sought to investigate the effect of the 2008–2009
seasonal influenza vaccine status on the risk of death among A/
H1N1-positive cases after adjustment for age, gender, geography,
admission delay (,= 2 days vs. .2 days), antiviral treatment, and
comorbidities. We also quantified the interaction between antiviral
treatment and admission delay to account for the fact that patients
admitted earlier in their disease course had a higher probability of
receiving antiviral treatment. Because the 2009 pandemic vaccine
was not available until December 2009 in Mexico [23], we did not
seek to include pandemic vaccination status in the model. The
effects of model predictors were measured using odds ratios (95%
CI) and P values. Records with missing data (e.g., admission delay,
comorbidities) were excluded from the analysis.
Observational studies like ours are prone to confounding bias
due to their inherent observational nature [24]. To assess
confounding bias, we compared our findings based on A/H1N1-
positive inpatients with those based on A/H1N1-negative
inpatients. Specifically, we analyzed the risk of death in the group
of A/H1N1-negative inpatients using multivariate logistic re-
gression after adjustment for age, gender, geography, admission
delays (,= 2 days vs. .2 days), antiviral treatment, the 2008–
2009 seasonal influenza vaccine status, and underlying comorbid-
ities and other medical conditions.
Ethics Committee approval was not necessary according to local
regulations as all the data were de-identified and information used
in this study is routinely collected for epidemiological surveillance
purposes.
Statistical analyses were performed using PASW Statistics 18.0.
Results
Hospital admission delay and length of stay
Out of the 10435 ARI hospitalizations recorded during the fall
pandemic wave, the number of A/H1N1-positive hospitalizations
Determinants for Mortality of 2009 H1N1 in Mexico
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41069
and inpatient deaths were 2944 and 517, respectively (Figure 1).
The case fatality proportion was significantly higher among male
A/H1N1 inpatients compared to females (17.3% vs. 13.1%, Chi-
square test, P = 0.001). The great majority of laboratory-confirmed
influenza inpatients were 18–49 y (51.7%) followed by persons
,18 y (31%) and those .50 y (17.3%). The case fatality
proportion increased with older age from 7.4% for persons
,18 y, 16.6% for persons 18–49 y, and 23.5% for persons
.= 50 y.
The average time from symptoms onset to admission among A/
H1N1-positive inpatients was 3.1 days (95% CI: 3.0, 3.3) while the
average length of hospital stay was 5.3 days (95% CI: 5.1, 5.6), but
it was significantly longer for A/H1N1 inpatients with fatal
outcomes than for those who recovered (4.9 days (95% CI: 4.7,
5.1) vs. 7.7 (95% CI: 7.0, 8.4), Wilcoxon test, P,0.0001). Among
A/H1N1 inpatients that recovered, the length of hospital stay was
4.1 days (95% CI: 3.9, 4.3) among inpatients with admission
delays ,= 2 days compared to inpatients with admission delays
.2 days (5.8 days (95% CI: 5.4, 6.2), Wilcoxon test, P,0.0001).
Clinical symptoms
The most common signs and symptoms among A/H1N1-
positive inpatients were cough, malaise, headache, and fever as
shown in Table 1. Dyspnea, cyanosis, and prostration at
presentation were significantly associated with the risk of death
among A/H1N1-positive inpatients after adjustment for age,
gender, and geography using a multivariate logistic regression
framework (Table 1). For comparison, dyspnea, cyanosis, and
thoracic pain were statistically significant risk factors of death
among A/H1N1-negative inpatients, but presence of prostration
was not statistically significant.
Underlying risk factors
A comparison of the characteristics of A/H1N1-postive and A/
H1N1-negative inpatients including age, gender, geography,
comorbidities, antiviral treatment, admission delays, and 2008–
2009 seasonal influenza vaccine status is shown in Table 2. Among
inpatients with confirmed A/H1N1, one or more comorbidities
were present in 16.5% of A/H1N1 inpatients under 18 years of
age and in 32.2% of inpatients 18 years and older. The most
common comorbidities among A/H1N1 inpatients were obesity
(11.8%) and diabetes (9.1%) (Table 3). In univariate logistic
regression analyses, diabetes, immune suppression, smoking and
obesity were significantly associated with an increase risk of death
among A/H1N1-positive inpatients while asthma and pregnancy
were significantly associated with a reduced risk of death among
A/H1N1-positive inpatients (Figure 2). Similar effects were
observed in our comparison group of A/H1N1-negative inpatients
(Figure 2). In an adjusted multivariate logistic regression analysis of
the risk factors for dying from A/H1N1 influenza ARI hospital-
ization, we found diabetes (OR = 1.55 (95% CI: 1.11, 2.16)) and
immune suppression (OR = 2.29 (95% CI: 1.49, 3.51)) to be
statistically significant risk factors while asthma (OR = 0.34 (95%
CI: 0.17, 0.68)) and pregnancy (OR = 0.43 (95% CI: 0.25, 0.74))
were significantly associated with a reduced risk of death among
A/H1N1 inpatients with adjustment for age, gender, geography,
admission delay, antiviral treatment, and 2008–2009 seasonal
influenza vaccine status (Table 3). These risk factors had a similar
effect in our group of A/H1N1-negative inpatients (Figure 3).
A total of 1156 A/H1N1 influenza hospitalizations were among
women of childbearing age (15–49 y) of which 26.1% were
pregnant, 12.5% received antiviral medication and 7.2% reported
receipt of the 2008–2009 seasonal influenza vaccine. Among the
320 hospitalized pregnant women with A/H1N1, 10.9% received
antiviral medications and 8.4% had received the 2008–2009
seasonal influenza vaccine. The case fatality proportion among A/
H1N1 pregnant women was significantly lower than that of non-
pregnant women of childbearing age (5.3% vs. 15.3%, Chi-square
test, P,0.0001). Table S1 shows the risk for death for pregnant
women among women aged 15–49 years, stratified into 5-year age
groups, hospitalized with laboratory-confirmed A/H1N1 influen-
za. The average hospital length of stay was not significantly
different between pregnant women and non-pregnant woman of
childbearing age that recovered (4.5 d vs. 4.7 d, t-test, P = 0.57).
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Figure 1. Weekly number of new laboratory-confirmed A/H1N1 influenza outpatients, inpatients, and deaths by dates of symptoms
onset, August-December 2009 in Mexico.
doi:10.1371/journal.pone.0041069.g001
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2008–2009 seasonal influenza vaccine status
A total of 253 (7.3%) A/H1N1-positive inpatients reported
receipt of the 2008–2009 seasonal influenza vaccine while 274
(12.2%) of A/H1N1-negative inpatients reported receipt of the
seasonal vaccine. After adjusting for age, gender, geography, and
treatment with neuraminidase inhibitors in a multivariate logistic
regression framework, we found that immunization with the 2008–
2009 seasonal influenza vaccine was significantly protective against
death among A/H1N1 inpatients (OR = 0.32 (95% CI: 0.19,
0.55)). This significant protective effect was maintained even after
further adjustment for admission delays and underlying comor-
bidities and other medical conditions (OR = 0.43 (95% CI: 0.24,
0.74), Figure 3). By contrast, receipt of the seasonal influenza
vaccine by A/H1N1-negative inpatients was not statistically
associated with risk of death (OR = 0.67 95% CI: 0.35, 1.128)).
When this analysis was focused on the highest A/H1N1 incidence
month of October, we found consistent results with estimated
OR = 0.34 (95% CI: 0.12, 0.98). In contrast, for the low incidence
month of August, we found non –significant estimates 0.25 (95%
CI: 0.02, 2.7).
Antiviral treatment and admission delays
Only 8.9% of A/H1N1-positive inpatients and 6.5% of A/
H1N1-negative inpatients were treated with neuraminidase
inhibitors during the 2009 fall pandemic wave in Mexico.
Antiviral treatment was found to be a significant protective factor
against death given A/H1N1 hospitalization (OR = 0.64 (95% CI:
0.43, 0.93)) after adjustment for age, gender, geography, and
2008–2009 seasonal influenza vaccine status. However, it was not
statistically significant after further adjustment for admission delay
and underlying medical conditions (OR = 0.56 (95% CI: 0.29,
1.10), Figure 3) perhaps due to the small fraction of inpatients
treated with antivirals in the fall while admission delays .2 days
significantly increased the risk of death among A/H1N1 inpatients
(OR = 2.66 (95% CI: 2.11, 3.35)). Antiviral treatment was not
statistically significant for the group of A/H1N1 inpatients with
admission delays ,= 2 days (OR = 0.52 (95% CI: 0.26, 1.04)) and
for the group with admission delays .2 days (OR = 0.949 (95%
CI: 0.56, 1.60)) after adjustment for all other covariates. We note
that admission delays .2 days were also significantly associated
with an increased risk of death among A/H1N1-negative
inpatients (OR = 1.94 (95% CI: 1.32, 2.87)) after adjustment for
other covariates.
Discussion
In this study we have analyzed the clinical features, risk factors,
and the effect of the 2008–09 trivalent inactivated influenza
vaccine status on the risk of death using a large series of 10435
ARI inpatients during the fall pandemic wave (August –
December, 2009) associated with most pandemic deaths in
Mexico. Our results indicate that prior vaccination with the
2008–2009 seasonal influenza vaccine was significantly associated
with a reduced risk of death among laboratory-confirmed A/
H1N1 inpatients after adjustment for demographic and geo-
graphic information, comorbidities and other medical conditions,
antiviral treatment, and admission delays using multivariate
logistic regression. Nevertheless, this protective vaccine effect
needs to be interpreted with caution as it could have been affected
by factors not directly measured in our study (e.g., healthy
vaccinee effect [25,26]). Our findings also underscore the
important role of underlying medical conditions such as diabetes
and immune suppression and hospital admission delays in
increasing the risk of death in patients hospitalized with A/H1N1.
Studies of the cross-reactive antibody response to a novel
influenza A (H1N1) virus after vaccination with the 2008–2009
Table 1. Frequency of clinical characteristics of laboratory-confirmed A/H1N1inpatients and fatal cases, Mexico, August-December
2009.
Clinical features
A/H1N1 hospitalizations
for surviving patients A/H1N1 deaths
A/H1N1-inpatient vs
A/H1N1 death
odds ratio (95% CI)a
Fever 2365/2940 (80.4) 397/516 (76.9) 0.95 (0.73, 1.24)
Cough 2728/2940 (92.8) 474/516 (91.9) 0.96 (0.65, 1.42)
Headache 2462/2940 (83.7) 387/516 (75) 0.82 (0.62, 1.08)
Sore throat 1686/2940 (57.3) 257/516 (49.8) 0.86 (0.69, 1.07)
Malaise 2536/2940 (86.3) 439/516 (85.1) 1.07 (0.78, 1.49)
Myalgia 2156/2940 (73.3) 331/516 (64.1) 0.80 (0.56, 1.15)
Arthralgia 2059/2940 (70) 315/516 (61) 0.97 (0.68, 1.38)
Prostration 1676/2940 (57) 334/516 (64.7) 1.38 (1.10, 1.75)
Rhinorrhea 2055/2940 (69.9) 264/516 (51.2) 0.53 (0.43, 0.66)
Chills 1942/2940 (66.1) 289/516 (56) 0.73 (0.58, 0.93)
Abdominal pain 865/2940 (29.4) 141/516 (27.3) 0.92 (0.72, 1.17)
Conjuntivitis 973/2940 (33.1) 100/516 (19.4) 0.53 (0.41, 0.69)
Dyspnea 1559/2940 (53) 406/516 (78.7) 2.63 (2.04, 3.40)
Cyanosis 205/2940 (7) 148/516 (28.7) 4.58 (3.50, 6.01)
Diarrhea 371/2940 (12.6) 82/516 (15.9) 1.17 (0.87, 1.57)
Thoracic pain 1425/2940 (48.5) 271/516 (52.5) 0.95 (0.75, 1.19)
Coryza 354/2940 (12) 42/516 (8.1) 0.64 (0.43, 0.93)
aadjusted by age, gender, and geography.
doi:10.1371/journal.pone.0041069.t001
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seasonal influenza vaccine indicated a small or no increase in
antibodies against the novel 2009 swine-origin A/H1N1 influenza
virus [27,28,29]. However, it was unknown whether such levels of
cross-reactive antibody were able to confer any protection against
novel influenza A/H1N1. In addition, the results of immunoinfor-
matic studies that compared T-cell epitopes contained in novel
2009 A/H1N1 virus with epitopes in 2008–2009 conventional
influenza vaccine suggested certain degree of protection against
novel A/H1N1 [30,31]. Furthermore, T cell-mediated immunity
after influenza vaccination or natural infection has been shown to
play an important role in heterotypic immunity [32,33,34]. From
October 2008 to March 2009, approximately 14% of the IMSS-
affiliated population were vaccinated with 2008–09 trivalent
inactivated influenza vaccine (TIV) (79% among infants ,3 years
and 61.7% among seniors .= 60 years) [35]. Besides, reactive
vaccination with the 2008-200 TIV seasonal vaccine was
conducted in Mexico during the early 2009 pandemic period that
included the administration of 1 million vaccine doses in the
Federal District, but we were unable to ascertain cumulative
seasonal influenza vaccination rates prior to the fall pandemic
wave. Our results indicate that A/H1N1 inpatients vaccinated
with the 2008–2009 seasonal influenza vaccine had a significant
reduced risk of death (adjusted OR = 0.43; after controlling for
age, gender, geography, comorbidities, antiviral treatment, and
admission delay). We note that two earlier observational studies
found a similar protective effect, based on a substantially smaller
sample size than used here from the first months of the pandemic
(April – July, 2009) in Mexico. These studies suggested a significant
protective effect of 35%–73% against infection, particularly severe
forms of the disease during the early pandemic phase [20,21]. By
contrast, other epidemiological studies have found no association
[24,36,37,38,39,40,41,42] or a mild benefit [43,44] against
infection or hospitalization with laboratory-confirmed pandemic
A/H1N1 from the 2008–2009 seasonal influenza vaccine.
However, these studies did not quantify the effect of seasonal
influenza vaccine against death associated with pandemic A/
H1N1 infection. By contrast, Canadian studies using data from the
provinces of Alberta, British Colombia, Ontario, and Quebec
[45,46] reported the opposite effect with seasonal influenza
vaccination in the previous season, with a significantly associated
increased risk of A/H1N1 illness by 1.03- to 2.74-fold, after careful
adjustment for comorbidities, age, and geography although this
risk did not extend to hospitalized patients [47].
Risk of death among A/H1N1 influenza inpatients increased by
a factor of 2.66 (95% CI: 2.11, 3.35) with admission delays
.2 days after adjusting for other covariates, which is in line with
previous studies [48,49,50,51]. Overall the distribution of admis-
sion delays in our study is similar to that reported in other studies
[50,52,53,54]. This finding suggests that late access to medical
10−1 100 101 102 103 104
cases:1.46(0.544−3.9) Lactating mother
cases:0.3(0.18−0.49) Pregnancy
cases:2.08(0.66−6.55) HIV/AIDS
cases:2.15(1.67−2.77) Obesity
cases:1.68(1.23−2.27) Smoking
cases:2.36(1.67−3.33) Immune compromised
cases:0.3(0.17−0.54) Asthma
cases:2.4(1.83−3.12) Diabetes
cases:1.23(0.73−2.06) Chronic obstructive pulmonary disease (COPD)
cases:0.67(0.46−0.97) Antiviral treatment
cases:3.43(2.8−4.2) Admission delays
cases:0.34(0.2−0.58) 2008−2009 seasonal influenza vaccine
controls:1.44(0.43−4.84)
controls:0.14(0.019−0.98)
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controls:2.12(1.53−2.95)
controls:0.62(0.37−1.06)
 Univariate odds ratio and 95% CIs
Figure 2. Results of univariate logistic regression analyses of the risk of death among inpatients based on A/H1N1-positive
inpatients and A/H1N1-negative inpatients (controls). The effects of model predictors were measured using odds ratios and corresponding
95% CIs.
doi:10.1371/journal.pone.0041069.g002
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care could explain an important fraction of the 2009 A/H1N1
influenza pandemic mortality burden in Mexico.
We identified some symptoms – dyspnea, cyanosis, and
prostration – at presentation that were statistically significant
predictors of death among A/H1N1-positive inpatients after
adjusting by age and gender, in agreement with three previous
reports [20,55,56].
Presence of diabetes (OR = 1.55 (95% CI: 1.11, 2.16)) and
immune suppression (2.29 (95% CI: 1.49, 3.51)) were statistically
significant risk factors of mortality among A/H1N1 inpatients in
an adjusted multivariate logistic regression analysis. A similar
effect was observed in the group of A/H1N1-negative inpatients
(Figure 3). Of note, a national survey conducted among IMSS
affiliated population in 2010 indicated that 6.2% of persons aged
20–59 years and 28.1% of persons older than 60 years had been
previously diagnosed with diabetes mellitus. Furthermore, a retro-
spective study found diabetes and class III obesity to be
significantly associated with death from pandemic A/H1N1
influenza in Southern Brazil [57]. In our study obesity was not
a significant risk factor after controlling for diabetes and other
underlying medical conditions using our multivariate logistic
regression modeling framework applied to individual-level clinical
data. In our data, 9.1% of A/H1N1 inpatients had diabetes,
11.8% of A/H1N1 inpatients were obese, and 2.6% of A/H1N1
inpatients were obese and diabetic. Several studies have supported
a link between obesity and increased risk of death with seasonal
influenza [58] and 2009 pandemic A/H1N1 influenza
[8,10,11,43,57,59,60]. Of note, Morgan et al. [8] found morbid
obesity to be significantly associated with 2009 A/H1N1 influenza
severe outcomes, and Yu et al. [3] found obesity to be a risk factor
among A/H1N1 hospitalizations in China.
Pregnancy was significantly associated with a reduced risk of
death among A/H1N1 inpatients (OR = 0.43 (95% CI: 0.25,
0.74)) in a multivariate logistic regression framework after
adjusting for admission delay and other covariates. A similar
effect was observed in the group of A/H1N1-negative inpatients
although it was not significant. It is possible that this apparently
paradoxical finding can be explained by a tendency to hospitalize
pregnant women for less severe influenza than age peers. In our
sample, pregnant women accounted for 26% of A/H1N1
influenza hospitalizations, which is in agreement with Trulove
et al. [61] who reported 27% of A/H1N1 hospitalizations among
women of childbearing age in Wisconsin. However, these
estimates are higher than the estimate of 19.6% reported for
Canada [62]. Variations in the association of pregnancy and
disease severity from A/H1N1 infections in different countries
have been attributed to differences in case management practices
[10,11,20,63,64].
We found asthmatic inpatients to be significantly associated with
a reduced risk of death among A/H1N1 inpatients (OR = 0.34
(95% CI: 0.17, 0.68)), which is in line with a multi-country risk
factor analysis of severe outcomes associated with pandemic A/
0.1 1.0 10 100
cases:1.97(0.697−5.57) Lactating mother
cases:0.451(0.256−0.796) Pregnancy
cases:1.3(0.348−4.82) HIV/AIDS
cases:1.32(0.982−1.77) Obesity
cases:0.975(0.679−1.4) Smoking
cases:2.29(1.49−3.51) Immune compromised
cases:0.338(0.169−0.679) Asthma
cases:1.55(1.11−2.16) Diabetes
cases:0.719(0.398−1.3) Chronic obstructive pulmonary disease (COPD)
cases:0.56(0.285−1.1) Antiviral treatment
cases:2.66(2.11−3.35) Admission delays
cases:0.425(0.245−0.738) 2008−2009 seasonal influenza vaccine
controls:5.47(1.43−20.9)
controls:0.281(0.036−2.17)
controls:3.54(0.992−12.6)
controls:0.977(0.585−1.63)
controls:1.26(0.751−2.13)
controls:1.91(1.04−3.52)
controls:0.473(0.165−1.36)
controls:1.7(1.08−2.68)
controls:0.734(0.343−1.57)
controls:0.637(0.187−2.17)
controls:1.94(1.32−2.87)
controls:0.673(0.355−1.28)
 Adjusted odds ratio and 95% CIs
Figure 3. Results of a multivariate logistic regression analysis of the risk of death among inpatients based on A/H1N1-positive
inpatients and A/H1N1-negative inpatients (controls) after adjusting for age, gender, geography, antiviral treatment, admission
delays, 2008–2009 seasonal influenza vaccine, comorbidities, and other medical conditions. The effects of model predictors were
measured using odds ratios and corresponding 95% CIs.
doi:10.1371/journal.pone.0041069.g003
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H1N1 infections [10]. Van Kerkhove et al. [10] found that
a higher proportion of hospitalized cases with asthma survived
compared to patients with other conditions. These researchers
explained this observation as the result of manageable influenza-
induced exacerbations of asthma prompting admission that do not
progress to viral pneumonia or other fatal complications. Another
study by O’Riordan et al. found asthma to be a risk factor for
severe disease among hospitalized children, but there was no clear
relationship with severity of asthma [6], and Ward et al. [11]
found asthma requiring regular preventive medication to be
associated with hospitalization from A/H1N1 influenza.
Treatment with antivirals during the fall pandemic wave was
not significantly associated with the risk of death among A/H1N1
inpatients after adjustment for admission delay and comorbidities
and other medical conditions. This result could be due to the small
fraction of hospitalized patients that were treated with antivirals
during the fall wave (,9%) and the fact that decision to treat was
not found to be related to symptoms severity [65]. We [65]
recently reported a sharp drop in antiviral use from 50% in the
spring and summer wave to 9% in the main fall pandemic in
Mexico. In addition, underlying confounding bias could have
played a role, such as delayed patients being more likely to die and
also being outside the ‘‘time window’’ of 48 hours when treatment
with neuraminidase inhibitors is considered clinically meaningful
[66,67].
Table 2. Characteristics of A/H1N1-positive and A/H1N1-negative inpatients and all ARI inpatients by age, gender, geography,
2008–2009 seasonal influenza vaccine status, and comorbidities and other medical conditions, Mexico, August-December 2009.
Variable
A/H1N1-positive
inpatients
A/H1N1-negative
inpatients All ARI inpatients
Geographic region
Central 1757 (50.8%) 1128 (50.3%) 4871 (46.7%)
Southern 375 (10.8%) 350 (15.6%) 1363 (13.1%)
Other states 1329 (38.4%) 766 (34.1%) 4197 (40.2%)
Demography
Female 1974 (57.1%) 1159 (51.9%) 5703 (54.9%)
Male 1482 (42.9%) 1073 (48.1%) 4685 (45.1%)
Age (years)
0–4 386 (11.2%) 674 (40.4%) 2055 (19.8%)
5–14 531 (15.4%) 191 (8.6%) 1271 (12.3%)
15–29 972 (28.1%) 334 (15%) 2208 (21.3%)
30–44 737 (21.3%) 420 (18.9%) 2145 (20.7%)
45–59 616 (17.8%) 336 (15.1%) 1731 (16.7%)
.= 60 212 (6.1%) 265 (11.9%) 961 (9.3%)
Admission delay .2 days 1396 (42%) 1144 (53.4%) 4779 (47.9%)
Antiviral treatment 306 (8.9%) 145 (6.5%) 768 (7.4%)
Comorbidities & medical conditions
Chronic obstructive pulmonary disease (COPD) 102 (3%) 102 (4.6%) 385 (3.7%)
Diabetes 313 (9.1%) 231 (10.4%) 959 (9.3%)
Asthma 227 (6.6%) 130 (5.9%) 680 (6.6%)
Immune compromised 174 (5.1%) 113 (5.1%) 513 (5%)
Smoking 274 (8%) 166 (7.5%) 766 (7.5%)
Obesity 383 (11.8%) 204 (9.3%) 1015 (10.3%)
HIV/AIDS 15 (0.4%) 15 (0.7%) 58 (0.6%)
Pregnancy 320 (9.3%) 77 (3.5%) 613 (6%)
Lactating mother 25 (0.8%) 26 (1.2%) 94 (1%)
2008–2009 TIV vaccinated
Total 253 (7.3%) 272 (12.2%) 964 (9.3%)
Age group
0–4 44 (17.4%) 128 (47.1%) 341 (35.4%)
5–14 32 (12.6%) 13 (4.8%) 72 (7.5%)
15–29 53 (20.9%) 23 (8.5%) 123 (12.8%)
30–44 41 (16.2%) 42 (15.4%) 145 (15%)
45–59 57 (22.5%) 37 (13.6%) 147 (15.2%)
.= 60 26 (10.3%) 29 (10.7%) 136 (14.1%)
doi:10.1371/journal.pone.0041069.t002
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Our study has several strengths and limitations worth noting.
We used data on a large series of ARI hospitalizations reported to
the largest Mexican Social Security medical system where about
one-third of cases were consistently tested for influenza over time
and across age groups and geographic regions, and we have
documented no evidence of weaker disease surveillance in smaller
states [18]. Our individual-level clinical data allowed us to assess
the effect of the 2008–2009 seasonal influenza vaccine status on
severe disease outcomes associated with novel A/H1N1 influenza
after controlling for demographic and geographic information,
comorbidities and other medical conditions, antiviral treatment
and hospital admission delays. Moreover, risk factor data were
recorded in most medical records with only obesity information
missing in 5.8% of inpatient records and other comorbidities
missing in 1%. Admission delay was missing in 4% of records, and
seasonal influenza vaccine status or antiviral treatment was missing
in 0.1% of records. We were not able to ascertain differences in
availability of critical case management and intensive care units by
geographical region. Some comorbidities namely cardiovascular
disease, renal disease, neurologic disorders, hematologic disease
and hepatic conditions were not recorded, but have been found to
be associated with severe disease from influenza infection
[68,69,70,71,72]. Hence, we cannot rule out residual confounding
bias in our study. Moreover, protective effects we observed against
death might be related to confounding by factors that were not
measured in our study such as the possibility that individuals who
are vaccinated tend to be healthier than individuals who are not
vaccinated (e.g., healthy vaccinee effect [25,26]). The fact that the
vaccine effect remained significant when the analysis was restricted
to the peak month of influenza circulation in October, but
disappeared when the analysis was restricted to August when
influenza circulation was low, suggests however that this bias is
limited.
We note that observational studies like ours are prone to
confounding bias due to their inherent observational nature. Of
note, study patients, who visited the IMSS facilities, were likely to
be representative of those patients with more severe disease, given
the representativeness of the IMSS system. Although the IMSS
population is representative of the age and gender of the general
Mexican population, our findings may not be representative of the
lower socio-economic sector which is not covered by IMSS. Lastly,
a subset of our A/H1N1-positive inpatients may have had
secondary bacterial infection, but co-infection data was not
available to evaluate the role of bacterial coinfections or antibiotic
treatment on risk of death associated with A/H1N1 infection
[73,74].
In summary, our findings suggest that the 2008–9 trivalent
inactivated vaccine was significantly associated with a reduced risk
of death from 2009 A/H1N1 influenza infection during the fall
pandemic wave in Mexico. Our study also highlights the role of
admission delays, and prevalence of diabetes and immune
suppression in explaining between-individual variation in 2009
A/H1N1 mortality risk, thereby potentially accounting for geo-
graphical variation in pandemic mortality rates across countries.
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